Kornimate/medical-research-clean huggingface dataset:
survival significance of molecular pathology and genetic variation in brain gliomas

Conditions: Glioma; Molecular Sequence Variation; Genetic Change

Summary: this study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, mr and histopathology images, molecular pathology and genetic data. this study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. this study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, mr and histopathology images, molecular pathology (1p/19q co-deletion, mgmt methylation, idh and tertp mutations, etc) and genetic data (whole exome sequencing, rna sequencing, proteomics, etc). this study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Eligibility criteria:
inclusion criteria: * patients must have radiologically and histologically confirmed diagnosis of primary glioma * life expectancy of greater than 3 months * must receive tumor resection * must have sufficient fresh frozen tissues for ngs * signed informed consent exclusion criteria: * no gliomas * no sufficient amount of tumor tissues for detection of molecular pathology * patients who are pregnant or breast feeding * patients who are suffered from severe systematic malfunctions * do not have sufficient fresh frozen tissues for ngs

Keywords: survival subgroup
infusion laboratory: protocol 1 - selegeline - 2

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to determine the effects of selegiline on the subjective and physiological effects of cocaine challenge in chronic crack abusers, and to evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.

to develop a medication for the treatment of cocaine addiction using a medical human physio-neuro-psycho-immunology laboratory setting. to characterize this cocaine abusing population on a variety of psychological and physicologically measures over time from withdrawal through pere and post cocaine administration. to determine the effects of selegeline on the subjective and physiological effects of cocaine challenge in chronic crack abusers. to evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.

Eligibility criteria:
inclusion criteria: m/f, ages 21-50. meet dsm-iv criteria for cocaine dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: cocaine dependence
bortezomib in treating patients with relapsed or refractory cutaneous t-cell lymphoma

Conditions: Lymphoma

Summary: rationale: bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. purpose: this phase ii trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous t-cell lymphoma.

objectives: * determine the response rates (complete response and partial response) and duration of response in patients with relapsed or refractory cutaneous t-cell lymphoma treated with bortezomib. * determine the safety and tolerability of this drug in these patients. outline: this is an open-label study. patients receive bortezomib iv over 3-5 seconds on days 1, 4, 8, and 11. treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed at 1 month and then at least every 3 months for 2 years or until disease progression. projected accrual: a total of 15-25 patients will be accrued for this study.

Eligibility criteria:
inclusion criteria: * histologically confirmed cutaneous t-cell lymphoma, including mycosis fungoides/sézary syndrome * stage ib-iv disease * relapsed or refractory disease or intolerant to ≥ 1 prior systemic therapy * measurable disease by radiological imaging or clinical finding * age over 18 * performance status karnofsky 70-100% * hematopoietic * wbc \> 2,000/mm\^3 * absolute neutrophil count \> 1,500/mm\^3 * platelet count \> 75,000/mm\^3 * hemoglobin \> 8.0 g/dl * hepatic * bilirubin \< 2 times upper limit of normal (uln) * ast and alt \< 3 times uln * renal * creatinine \< 1.5 times uln * creatinine clearance ≥ 30 ml/min * negative pregnancy test * fertile patients must use effective contraception * more than 3 months since prior high-dose chemotherapy * more than 30 days since prior and no other concurrent investigational drugs exclusion criteria: * history of myelodysplastic syndromes * evidence of cns disease * pregnant or nursing * peripheral neuropathy ≥ grade 2 * hypersensitivity to bortezomib, boron, or mannitol * serious medical condition or psychiatric illness that would preclude study participation * concurrent immunotherapy * concurrent chemotherapy * concurrent steroid dose \> 10 mg/day of prednisone or its equivalent * concurrent radiotherapy * concurrent surgery for the malignancy

Keywords: recurrent mycosis fungoides/sezary syndrome stage i mycosis fungoides/sezary syndrome stage ii mycosis fungoides/sezary syndrome stage iii mycosis fungoides/sezary syndrome stage iv mycosis fungoides/sezary syndrome stage i cutaneous t-cell non-hodgkin lymphoma stage ii cutaneous t-cell non-hodgkin lymphoma stage iii cutaneous t-cell non-hodgkin lymphoma stage iv cutaneous t-cell non-hodgkin lymphoma recurrent cutaneous t-cell non-hodgkin lymphoma
pemetrexed and cisplatin in advanced urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: pemetrexed has demonstrated a favorable response with minimal toxicity when used as single agent as first-line and second-line treatment for advanced urothelial carcinoma. the response rates were 32% and 28% for the first-line and second-line setting, respectively. cisplatin is one the most active chemotherapeutic agents in urothelial cancer, frequently used as combination chemotherapy such as gp (gemcitabine plus cisplatin) or mvac (methotrexate, vinblastine, adriamycin, and cisplatin). pemetrexed and cisplatin showed favorable activity profile in advanced non-small cell lung cancer with highly favorable toxicity profile. this study is to assess the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of urothelial (transitional cell) carcinoma with the exception of micropapillary subtype * patients must have recurrent disease (locally advanced or metastatic) that is not amenable to local therapy or newly diagnosed distant metastatic disease * measurable disease defined by recist v.1.0 * ecog performance status of 2 or better * adequate organ and bone marrow function defined as exclusion criteria: * other tumor type than urothelial carcinoma * presence or history of cns metastasis * prior systemic chemotherapy or immunotherapy (but prior local intravesical chemotherapy or immunotherapy was allowed. and recurrent disease after adjuvant or neoadjuvant cisplatin-based systemic chemotherapy is allowed if the last chemotherapy was administered 1 year or more before the patient enrollment.) * presence of second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) * peripheral sensory neuropathy grade 2 or worse * other serious illness or medical conditions

Keywords: advanced urothelial carcinoma
systematically assessing effects of colored light on humans with a multi-modal approach (substudy 7 of 7)

Conditions: Exposure to Man-made Visible Light

Summary: note: this is the seventh of in total 7 sub-studies related to the ethics committee of the canton of bern ref. no. kek-be 2016-00674. this sub-study includes 50 participants and 8 arms, in total 350 participants will be assessed in all 7 sub-studies. general study information: this is a randomized, cross-over, quantitative study, which investigates physiological variables, mood, and affect of healthy participants in response to colored light exposure. the participants take part in 5-8 arms and are exposed to colored light only, or are additionally asked to solve cognitive tasks during the colored light exposure. primary aim is to measure the change in several physiological variables, mood, and affect during colored light exposure of 15 or 45 minutes. the risk for the participants is negligible and comparable to the risk during daily life.


Eligibility criteria:
inclusion criteria: * normal color vision * right handed * written informed consent exclusion criteria: * smoking * any kind of diagnosed sleep disorder or neurological or psychiatric disorder in the last 3 months * acute severe traumas * chronic diseases with the necessity for medication * use of recreational drugs * regular intake of medication that would affect the outcome measures * regular excessive alcohol use (\> 18 standard units / week) * transmeridian travel in the last month (crossed \> 1 time zone border) * night shift word during the last month

Keywords: cerebral oxygen metabolism functional near-infrared spectroscopy partial pressure of carbon dioxide heart rate variability blood pressure affect mood respiration systematic randomized cross-over study systemic physiology electro-dermal activity pulse-respiratory quotient
aspirin dose and atherosclerosis in patients with heart disease

Conditions: Cardiovascular Diseases; Atherosclerosis; Myocardial Infarction

Summary: the purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients who have had a heart attack.

aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in patients who have survived a prior event as well as during an acute heart attack. low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots. our research is designed to explore whether higher doses of aspirin provide additional benefits on markers of atherosclerosis.

Eligibility criteria:
inclusion criteria: 1. age 40 to 80 years, inclusive. 2. patients with stable coronary disease, with and without diabetes mellitus, defined by: 1. angiographic evidence of 70% or greater stenosis, or 2. previous percutaneous coronary intervention (pci), or 3. coronary artery bypass graft (cabg), or 4. history of a mi, or 5. positive exercise test exclusion criteria: 1. patients taking greater than 81mg aspirin daily. 2. patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ace-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins. 3. patients within 6 months of a coronary intervention, including pci or cabg. 4. patients with a planned coronary intervention. 5. patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (nsaids) or anticoagulant drugs such as warfarin. 6. patients who are currently cigarette smokers. 7. women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy. 8. patients with any coagulation, bleeding or blood disorders. 9. patients who are sensitive or allergic to aspirin. 10. patients with documented history of any gastrointestinal disorders, including bleeding ulcers. 11. patients with any evidence of cancer or kidney, liver, lung, blood, or brain disorders. 12. patients with asthma, rhinitis, or nasal polyps. 13. patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the trial results, be indicative of an underlying disease state, or compromise the safety. 14. patients with class iv heart failure. 15. patients with severe aortic insufficiency, or aortic regurgitation. 16. patients with hearing loss or tinnitus. 17. patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.

Keywords: cardiovascular diseases aspirin atherosclerosis myocardial infarction
"goliath" - general or local anaestesia in intra arterial therapy

Conditions: Stroke; Anesthesia; Cerebral Revascularization

Summary: patients suffering a stroke with a large vessel occlusion is often treated intra veneous thrombolyse and on top of that also intra arterial therapy. it is unknown what form of anaestesia is best during intra arterial therapy. the investigators will randomize these patients between general anaestesia and local anaestesia. outcome will be growth of the ischemic lesion as judged on an mri scan.


Eligibility criteria:
inclusion criteria: * nihss\>10 * mrs=\<2 * groin puncture\<6hours from stroke onset * occlusion of ica, ica-t, m1, m2 exclusion criteria: * mri contraindications * gcs\<9 * intubated prior to arrival * posterior circulation stroke * allergy to anestetics
long-term follow-up study for subjects with chb previously treated with imdusiran (ab729)

Conditions: Long Term Follow-up

Summary: this is a long term follow-up study for chronic hepatitis b (chb) subjects who have received imdusiran treatment in a prior clinical trial, stopped na therapy during that trial, and remain off therapy. subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[eos\] visit) from their imdusiran clinical trial (the "parent study"). no interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or na therapy if restarted. study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off na therapy, inclusive of parent study participation).


Eligibility criteria:
key inclusion criteria: * have participated in a prior imdusiran clinical trial, * have discontinued na therapy in that trial and remain off na therapy, * have completed less than 3 years of follow-up visits after na discontinuation in the parent study. * have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements. exclusion criteria: * not applicable
the effects of therapy with teriparatide on vascular compliance and osteoprotegerin/rankl

Conditions: Osteoporosis

Summary: the purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and rankl levels (bone cells).

research subjects participation is about 6 months. subjects will give themselves daily injections of teriparatide after instruction on technique.

Eligibility criteria:
inclusion criteria: * postmenopausal women and men over the age of 40 who are starting therapy with teriparatide exclusion criteria: * patients with diabetes mellitus * current smokers * patients with a history of organ transplantation * patients currently of previously on glucocorticoid therapy within the past year * patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (bp 140/90 or greater) * patients ineligible for teriparatide therapy: history of metabolic bone disease other than osteoporosis * history of radiation therapy * patients pregnant or nursing * history of bone metastasis or skeletal malignancies * history of hypercalcemia
a phase iib study to investigate the efficacy and tolerability of cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) given intravenously to subjects with acute decompensated chronic congestive heart failure (adhf)

Conditions: Heart Failure; Heart Decompensation

Summary: a placebo controlled, double-blind and randomized study to assess different doses of a new drug (bay58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.


Eligibility criteria:
inclusion criteria: * male and non-pregnant, non-lactating female subjects, age \>/= 18 years of age; or women without childbearing potential defined as postmenopausal women aged 55 years or older, women with bilateral tubal ligation, women with bilateral ovarectomy, and women with a hysterectomy * subjects must have the clinical diagnosis of congestive heart failure (chf) made at least three months prior to enrollment * subjects must experience worsening of both of the symptoms below leading to hospitalization at the time of entry into the study: dyspnea and clinical evidence of volume overload exclusion criteria: * acute de-novo heart failure * acute myocardial infarction and/or myocardial infarction within 30 days * valvular heart disease requiring surgical intervention during the course of the study * heart failure due to or associated with uncorrected primary valvular disease, malfunctioning artificial heart valve, or uncorrected congenital heart disease * primary hypertrophic cardiomyopathy * acute inflammatory heart disease, eg, acute myocarditis * unstable angina requiring angiography

Keywords: heart failure
diagnostic of lewy body dementia by combining scintigraphy (spect) using a specific transporter and magnetic resonance imaging (mri)

Conditions: Lewy Body Dementia

Summary: the aim of this study is to improve the diagnostic of lewy body dementia by combining the scintigraphy (spect) usig a spécific transporter and magnetic resonance imaging (mri).

lewy body dementia is the second leading cause of dementia in france after degenerative alzheimer's disease. however its dignosis is difficult. its comes in large part from the similarity of symptoms with another close dementia syndrome : the alzheimer disease . therfore, its is very important to have a mean to distinguish between the two dementias. one highlight of the lewy body dementia process being dopaminergic degeneration, the use of specific radioactive tracers is thought to be the way. the radiotracer that has the greatest advantage for these explorations is currently the datscan because it binds specifically on the dopamine transporter and can be used in single photon emission computed tomography (spect). the aim of this study is to improve the performance of imaging in the diagnosis of dementia by combining scintigraphy (spect) and magnetic resonance imaging (mri) in the exploration of the striatal region . the development of this method applied to a population of subjects, with hallucinations and cognitive disorders, should demonstrate the value and complementarity of metabolic images (spect) and morphological (mri) within the differential diagnosis of lewy body dementia and the alzheimer disease . from a methodological point of view, the patient will be included in hospital and will have a clinical diagnosis defined according to the criteria of dementia nincds-adrda for the alzheimer disease and mc-keith criteria for lewy body dementia. their mmse will be over 18 and they have in common recurrent visual hallucinations. after the inclusion, two steps must be distinguished, a neuropsychological evaluation stage and an scitigraphy exploration . before the spect , all patients should have an mri.

Eligibility criteria:
inclusion criteria: * patients with alzheimer disease following nincds-adrda scale or lewy body dementia following mc keith scale. * aged between 65 et 90 years * patients with visual hallucination * patients with helping people * patients with mmse (mini mental state examination) equal or more than 18. * signed consent exclusion criteria: * hospitalized patients without their consent * patients who have not passed the neuropsychological tests * patients with a mmse less than 18 * patients without helping * patients with no visual hallucinations * patients with severe somatic pathology. * pregnancy * allergy to iodine
apatinib in combination with s-1 as first-line treatment in patients with advanced gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of apatinib combined with s-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.


Eligibility criteria:
inclusion criteria: 1. adult patients, aged ≥18 years; 2. histologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease; 3. measurable disease, according to the response evaluation criteria in solid tumors (recist v1.1); 4. eastern cooperative oncology group (ecog) performance status of 0 - 3; 5. no previous chemotherapy for advanced/metastatic disease 1) prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study); 2) no previous targeted therapy; 3) for patients who can't tolerate first-line chemotherapy or refuse to accept chemotherapy, if they request to participate in this study, may receive apatinib monotherapy after consultation with the principal investigator in consideration of ethics. 6. hematological, biochemical and organ functions: hb ≥ 80 g/l, anc ≥ 1.5×109/l, plt ≥ 80×109/l, bil \< 1.5×uln, alt or ast \< 2.5×uln (or \< 5×uln in patients with liver metastases), serum cr ≤ 1×uln, cr clearance ≥ 50 ml/min; 7. life expectancy of more than 3 months; 8. duration from operation is more than 4 weeks; 9. for women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. they will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. for men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. 10. signed informed consent. exclusion criteria: 1. patients with poor-controlled arterial hypertension (systolic blood pressure \> 140 mmhg or diastolic blood pressure \> 90 mm hg) despite standard medical management; coronary heart disease, arrhythmia (including qt interval prolongation, for man \> 450 ms, for woman \> 470 ms), and cardiac dysfunction greater than class ii; 2. factors affecting the oral medication, such as inability to swallow, chronic diarrhea and intestinal obstruction; 3. patients with a clear tendency of gastrointestinal bleeding; 4. abnormal coagulation function (inr \> 1.5×uln, aptt \> 1.5×uln), with tendency of bleed; 5. pregnant or lactating women; 6. other conditions regimented at investigators' discretion.